Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394450 | 0.92 | USP2 (0.52) | SMN1; SMN2USP2NR1H2HPGDRORC | |
| SCHEMBL18711285 | 0.86 | CYP4F2 (0.47) | SMN1; SMN2USP2HPGDCYP4F2CYP4A11 | |
| SCHEMBL18711499 | 0.86 | USP2 (0.49) | SMN1; SMN2USP2HPGDEPHX2CYP4F2 | |
| SCHEMBL995814 | 0.86 | ACACB (0.47) | SMN1; SMN2USP2HPGDCYP4F2CYP4A11 | |
| SCHEMBL18711501 | 0.86 | CYP11B2 (0.48) | SMN1; SMN2USP2RORCCYP4F2CYP4A11 | |
| SCHEMBL22092923 | 0.85 | USP2 (0.46) | SMN1; SMN2USP2NR1H2HPGDEPHX2 | |
| SCHEMBL22092949 | 0.85 | USP2 (0.46) | SMN1; SMN2USP2NR1H2HPGDEPHX2 | |
| SCHEMBL16064447 | 0.85 | USP2 (0.46) | SMN1; SMN2USP2NR1H2HPGDRORC | |
| SCHEMBL16573803 | 0.84 | USP2 (0.48) | SMN1; SMN2USP2NR1H2HPGDEPHX2 | |
| SCHEMBL22105585 | 0.83 | USP2 (0.44) | SMN1; SMN2USP2NR1H2HPGDRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | SOPONPONG JAKAPUN (TH) | 2025-11-27 | — | — | US | disclosed |
| US-12428419-B2 | Therapeutic compounds | GENENTECH, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025083426-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LIMITED (GB) | 2025-04-24 | — | — | WO | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2025032254-A1 | ANTHRACYCLINE DERIVATIVES AND CONJUGATES AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-02-13 | — | — | WO | disclosed |
| US-20240383897-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-4384517-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | Genentech, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11993599-B2 | Therapeutic compounds | GENENTECH, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2569300-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | SMN1; SMN2 1563/4885USP2 3450/4885NR1H2 705/4885 |
| US-11993599-B2 | Therapeutic compounds | BRDT, BRPF3, SNRPE | SMN1; SMN2 415/4885USP2 2053/4885NR1H2 1114/4885 |
| US-20240383897-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | SMN1; SMN2 415/4885USP2 2053/4885NR1H2 1114/4885 |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | SMN1; SMN2 2854/4885USP2 4231/4885NR1H2 2885/4885 |
| US-12428419-B2 | Therapeutic compounds | BRDT, BRPF3, SNRPE | SMN1; SMN2 415/4885USP2 2053/4885NR1H2 1114/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | SMN1; SMN2 1563/4885USP2 3450/4885NR1H2 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.